Syndax Pharmaceuticals In... (SNDX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 13.63 |
Market Cap | 1.22B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.64 |
PE Ratio (ttm) | -3.91 |
Forward PE | n/a |
Analyst | Buy |
Ask | 14.5 |
Volume | 1,379,962 |
Avg. Volume (20D) | 2,360,610 |
Open | 14.28 |
Previous Close | 14.36 |
Day's Range | 14.07 - 14.56 |
52-Week Range | 12.06 - 25.34 |
Beta | undefined |
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...
Analyst Forecast
According to 10 analyst ratings, the average rating for SNDX stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 159.92% from the latest price.
Next Earnings Release
Analysts project revenue of $21.98M, reflecting a n/a YoY growth and earnings per share of -1.07, making a 7.00% increase YoY.
Why Price Moved
News
2 months ago · seekingalpha.com
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy OpportunityPrimary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action da...
2 months ago · seekingalpha.com
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call TranscriptSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive...